Katharine Offer
A5048533068- Hematopoietic Stem Cell Transplantation
- Renal Transplantation Outcomes and Treatments
- Acute Lymphoblastic Leukemia research
- Sarcoma Diagnosis and Treatment
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Childhood Cancer Survivors' Quality of Life
- Bone Tumor Diagnosis and Treatments
- Virus-based gene therapy research
- Cancer-related molecular mechanisms research
- Adolescent and Pediatric Healthcare
- Lymphoma Diagnosis and Treatment
- Innovations in Medical Education
- Melanoma and MAPK Pathways
- Advances in Oncology and Radiotherapy
- Pharmacological Effects and Toxicity Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Primary Care and Health Outcomes
- Cancer-related Molecular Pathways
- Diversity and Career in Medicine
- CAR-T cell therapy research
- Gastrointestinal Bleeding Diagnosis and Treatment
Hackensack Meridian Health
2021-2023
Children's Cancer and Blood Foundation
2019-2020
Weill Cornell Medicine
2019-2020
Cornell University
2019-2020
Columbia University
2014-2016
Morgan Stanley Children's Hospital
2014
Only a few studies in children have evaluated the efficacy of prophylactic regimens using tacrolimus on acute graft-versus-host disease (aGVHD). As result, optimal levels after matched sibling donor allogeneic hematopoietic cell transplantation (alloHCT) are not well defined. We measured association between subtherapeutic (<10 ng/mL) during weeks 1 to 4 alloHCT and cumulative incidence grades II IV aGVHD children. Additionally, we identified lower cutoff for tacrolimus. Sixty patients...
Tacrolimus (FK506) is a calcineurin inhibitor and an essential component of many immunosuppressive regimens. The oral bioavailability tacrolimus may be affected by factors, including patient age gender, as well drug-drug interactions or genetic polymorphisms in drug metabolism. dosing recommendations for pediatric allogeneic hematopoietic cell transplantation (alloHCT) recipients have been derived from use adult solid-organ patients. Data describing the impact conversion i.v. to on incidence...
The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Abstract Osteosarcoma is the most common bone tumor in children and young adults. Metastatic relapsed disease confer poor prognosis, there have been no improvements outcomes for several decades. The disease's biological complexity, lack of drugs developed specifically osteosarcoma, imperfect preclinical models, limits existing clinical trial designs contributed to progress. Children's Oncology Group Bone Tumor Committee established New Agents Task Force identify prioritize agents inclusion...
A recent survey of pediatric hematology oncology (PHO) physicians identified that a majority believe fellows are struggling to find jobs align with their goals. Career development for trainees has historically been home institution-specific, limiting fellows' exposures career path possibilities. The "virtual-Symposium Pediatric Hematology/Oncology New York (v-SYMPHONY)" instituted tristate Development Series PHO better address needs and increase awareness the variety opportunities.The...
In an adult study, Nash et al. (Blood, 2000) recommended to maintain tacrolimus levels between 10-20ng/ml for aGVHD prophylaxis. The optimal range in children post-AlloHCT is not well defined. We studied the impact of mean and number days with subtherapeutic on incidence aGVHD. One-hundred eight patients received tacrolimus/ mycofenolate mofetil (MMF) prophylaxis March 2005 April 2012. Median age, 8 yrs; 37F/71M, malignant (n=61) nonmalignant (n=47) disorders. Stem cell source: 18 peripheral...
Limited data exists to determine the most appropriate conversion factor from IV PO administration of tacrolimus in children receiving for aGVHD prophylaxis following AlloHCT. The incidence and impact sub-therapeutic levels after is also not well described. We retrospectively studied association between length time achieve therapeutic (defined as >10ng/ml x 2 days) using currently accepted 4:1, grades I-IV aGVHD. consisted mycophenolate mofetil tacrolimus. Tacrolimus was initiated at a dose...